
From: Luis Diaz [Ldiaz1@jhmi.edu]
Sent: 12/27/2012 2:37:15 AM
To: amy.meister@merck.com; robert_iannone@merck.com
CC: bertvog@gmail.com; Dung Le [dle@jhmi.edu]
Subject: Clinical OCSP LOI for MK-3475 in MSI tumors
Attachments: Merck MSI Clinical LOI Dec 25, 2012 LD.doc

Amy and Robert-

I hope you are having a restful holiday. We received the LOI form and completed the application. It is attached for your review. As we discussed, we propose testing of MK-3475 in patients whose tumors are deficient in mismatch repair. The diagnostic test for MSI is commercially available and part of routine clinical care. The study is a straight-forward Simon two-stage design powered to response rate at 3 months and recruitment is feasible at our institution with perhaps 1-2 additional sites to improve the rate of accrual.

We are in the fortunate position to have some funding available for a study of this size, although we would welcome any support from Merck in addition to a supply of the drug. There is a timing issue with the funding and we'd like to allocate the necessary funds as soon as possible before this option disappears.

We are available to answer questions at any time and look forward to your comments.

Best,

Luis

Luis Diaz, M.D.
Associate Professor of Oncology
Ludwig Center for Cancer Genetics and Therapeutics
Johns Hopkins Kimmel Cancer Center
1650 Orleans Street, CRB I Room 590
Baltimore, MD 21231
410-955-8878 (office)
410-955-0548 (fax)